Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), H. Nunes (Bobigny, France), G. Criner (Philadelphia, Pennsylvania, United States of America), P. Sfikakis (Athens, Greece), W. Stevens (Melbourne, Victoria, Australia), C. Miede (Weimar (Lahn), Germany), M. Quaresma (Ingelheim, Germany), M. Alves (Ingelheim, Germany), G. Raghu (Seattle, Washington, United States of America). FVC decline in patients with SSc-ILD by use of anti-acid therapy. 3394

Member's Comments

No comment yet.

Related content which might interest you: Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 FEV6 and FEV1/FEV6 as an alternative for FVC and FEV1/FVC in monitoring response to prednisolone treatment Source: Annual Congress 2010 - Quality measurement and improvement in lung function Year: 2010 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients Source: Eur Respir J, 51 (4) 1702258; 10.1183/13993003.02258-2017 Year: 2018 Baseline FEV1and sputum neutrophils and macrophages predict the decrease in FEV1 after inhaled corticosteroid withdrawal in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 306s Year: 2004 Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 The efficacy of salmeterol/fluticasone (SF) for 6-month therapy in severe COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 30s Year: 2006 Distinguishing hyperinflation from combined restriction in patients with reduced FEV1/FVC and FVC on spirometry Source: Eur Respir J 2006; 28: Suppl. 50, 202s Year: 2006 The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020 Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Analysis of the post bronchodilator forced expiratory volume in one second of COPD patients clinically followed up for three years Source: Annual Congress 2013 –COPD diagnosis Year: 2013